"name","id","description","label","instanceType","rationale","uuid:ID"
"Study Design 1","StudyDesign_1","The main design for the study","","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","7413d6b1-6bf7-41f7-893d-ba98d9e82687"
